Why did GSK kill two vaccine R&D programs? CEO Emma Walmsley is glad you asked
As GlaxoSmithKline got deeper into its R&D reorganization under Hal Barron, the pharma giant — long known as the ponderous giant, lumbering from slow failure to slow failure — promised one thing above all: They would speed things up.
If a drug was designated as a top program worthy of a bigger investment, they would double down, as they have with their BCMA effort in the oncology group. If it looked weak or started to go downhill, there would be an unsentimental clearing of the decks.
If resources were freed in one area, they would flow to another.On Wednesday, GSK CEO Emma Walmsley was happy to step up to demonstrate how that works in daily practice.
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.